Cardiff Oncology, Inc. (CRDF)
NASDAQ: CRDF · Real-Time Price · USD
1.620
-0.060 (-3.57%)
Apr 29, 2026, 11:54 AM EDT - Market open
Cardiff Oncology Employees
As of December 31, 2025, Cardiff Oncology had 31 total employees, including 30 full-time and 1 part-time employees. The number of employees decreased by 2 or -6.06% compared to the previous year.
Employees
31
Change (1Y)
-2
Growth (1Y)
-6.06%
Revenue / Employee
$19,129
Profits / Employee
-$1,479,871
Market Cap
110.75M
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| Seer, Inc. | 124 |
| Cibus | 118 |
| Verrica Pharmaceuticals | 76 |
| InflaRx | 65 |
| PepGen | 56 |
| Vivani Medical | 42 |
| Biomea Fusion | 41 |
| Aardvark Therapeutics | 40 |
CRDF News
- 20 hours ago - Cardiff Oncology Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 2 days ago - Cardiff Oncology to Host Key Opinion Leader Discussion on Onvansertib's Promising Single-Agent Activity - GlobeNewsWire
- 8 days ago - Cardiff Oncology to Present Updated Phase 2 Data of Onvansertib in First-Line RAS-Mutated mCRC in a Rapid Oral Session at ASCO 2026 - GlobeNewsWire
- 11 days ago - Cardiff Oncology Presents Preclinical Data on its PLK1 Inhibitor Onvansertib in Combination with a HER2-Targeted ADC at the 2026 AACR Annual Meeting - GlobeNewsWire
- 19 days ago - Cardiff Oncology Announces Key Leadership Appointments to Strengthen Executive Team for Next Phase of Growth - GlobeNewsWire
- 4 weeks ago - Cardiff Oncology Transcript: KOL event - Transcripts
- 5 weeks ago - Cardiff Oncology to Host Key Opinion Leader Discussion Focusing on First-Line RAS-mutated Metastatic Colorectal Cancer - GlobeNewsWire
- 5 weeks ago - Cardiff Oncology to Present Preclinical Data with Highly Specific PLK1 Inhibitor Onvansertib at the 2026 AACR Annual Meeting - GlobeNewsWire